In industry briefings, Danaher disclosed a definitive agreement to acquire Masimo for roughly $9.9 billion, consolidating patient‑monitoring and oximetry technologies into Danaher’s diagnostics footprint. The broader news package also noted that Cepheid was selected as one of four national collaborators under a CDC IDIQ to accelerate rapid diagnostic development during public health emergencies. These moves signal continued consolidation among diagnostics and a parallel federal push to harden rapid assay pipelines for outbreak response.